Side effects of anticytokine strategies. by Meer, J.W.M. van der et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
M A R C H  2 0 0 5 ,  V O L .  6 3 ,  N O .  3
78
A B S T R A C T
Anticytokine strategies probably represent the most
important breakthrough in the treatment of inflammatory
diseases in the last decade. However, blocking the bio-
activity of proinflammatory cytokines, crucial activators of
host defence, has proved to be accompanied by an
increased susceptibility to infections, especially with
Mycobacteria, Salmonellae and fungal pathogens. Multiple
mechanisms for these side effects have been proposed,
such as inhibition of gamma-interferon production,
decreased expression of pattern-recognition receptors,
and leucocyte apoptosis. Caution is therefore warranted
when these treatments are given to patients with an
increased risk for infections. A range of side effects other
than infection have been reported.
Treatment strategies interfering with proinflammatory
cytokines such as tumour necrosis factor (TNF)  and
interleukin-1 (IL-1) constitute a breakthrough in the
treatment of rheumatoid arthritis (RA) and other
inflammatory disorders. However, some 10 to 15 years
ago it was demonstrated in experimental animals that
treatment with antibodies against TNF was deleterious in
mycobacterial infections, fungal infections and abscesses.
The exact mechanisms by which interference with TNF
produced these results were not entirely clear, but it was
concluded that containment of micro-organisms within
granulomas and abscesses was not achieved or main-
tained.1-3
Based on these observations, it was easy to predict that
large-scale and prolonged anti-TNF treatment in humans
would lead to infections, especially by organisms that
induce a granulomatous response. Indeed, such com-
plications (especially mycobacterial and Salmonella
infections) were readily encountered, but still seemed to
come as a surprise to the medical community. 
In this issue of the journal, Efde and colleagues report a
case of tonsillar tuberculosis, a rare manifestation of this
infectious disease, occurring during anti-TNF treatment.4
The occurrence of these infections has important impli-
cations for pretreatment assessment of patients, and
guidelines for this purpose are appearing, also in the
Netherlands.5 Two years ago, the Netherlands Journal of
Medicine published a state-of-the-art review by Arend et al.
on this topic with a detailed account of the literature
and a proposal for the management of patients at risk.6
The patient reported in this issue of the journal received
a six-month course of isoniazid for latent tuberculosis.
As noted in the review6 and by the authors of the case
report,4 a period of six months of isoniazid is not optimal.
It also implies that the risk of reactivation of tuberculosis
during anti-TNF treatment in patients harbouring dormant
bacilli should not be underestimated.
It is interesting that the risk for infection is greater with
the monoclonal antibodies against TNF (infliximab and
adalimumab) than with the TNF receptor construct
etanercept: during infliximab therapy the risk is estimated
to be 200 per 100,000 treatments, with etanercept it is 9
per 100,000.7 Theoretically, one would expect differences
between the various types of anti-TNF drugs, as they dif-
fer in their capacity to interact with TNF- and TNF-
(lymphotoxin), and with membrane-bound TNF. Another
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interesting, not well-explained observation is that treatment
with the recombinant interleukin-1 receptor antagonist,
IL-1Ra (anakinra), does not seem to lead to excess infection.
How inhibition of TNF impairs host defence in patients
is still enigmatic, but several mechanisms have been
suggested. Firstly, blockade of TNF itself can impair host
defence, as TNF is known to activate the microbicidal
properties of neutrophils and macrophages.8 Secondly,
TNF blockade can inhibit secondary activation of the
cytokine cascade. We have demonstrated in patients with
a serious Salmonella infection that interferon- production
was strongly inhibited.9 The role of the latter cytokine in
host defence against micro-organisms is much better
understood: a deficient response to this cytokine has
been shown to lead to serious infections.10-12 Important
questions that remain are whether all patients who receive
anti-TNF treatment respond with a down-regulation of
the interferon- response, and whether we can predict the
risk for infection by assessing the production of this
cytokine. It is also tempting to speculate that the capacity
to down-regulate the interferon- response explains the
difference in occurrence of infection between IL-1 inhibition
and TNF inhibition, but more research is needed to answer
this question. Other mechanisms of anti-TNF treatment
include down-modulation of pattern recognition receptors
such as TLR4,9 and leucocyte apoptosis.13 One may also
ask the question whether anticytokine treatment, for
example in patients with rheumatoid arthritis, has more
effects that are not intended. A range of side effects other
than infection have been reported, albeit with a lower
incidence.14
Treatment with TNF inhibitory agents has been associated
with rare cases of onset or exacerbation of demyelinating
disorders, which met with a partial or complete response
when treatment was stopped. In addition, despite the
elevated TNF concentrations in the cerebrospinal fluid
and in the circulation of multiple sclerosis (MS) patients,
blocking this cytokine resulted in a worsening of the
disease.15 The mechanisms underlying this side effect are
still unknown. 
Development of autoantibodies including antinuclear
antibody (ANA) and anti-double-stranded DNA have been
reported during therapy with anti-TNF agents. The clinical
relevance of this is uncertain, although post-marketing
surveillance reports mention cases of autoimmune diseases,
especially leucocytoclastic vasculitis and lupus-like syndrome,
improving after therapy was discontinued. 
Concerns have been raised about haematological disorders,
especially non-Hodgkin’s lymphoma, and cytopenia during
anti-TNF therapy. Very few cases have been reported in
patients with long-lasting RA receiving multiple drugs.
The role of anti-TNF drugs is therefore unknown.
Congestive heart failure proved to worsen by TNF blockade,
despite earlier studies predicting the opposite: chronic heart
failure (CHF) was associated with elevated production of
TNF. Trials intended to show the benefit of suppressing
TNF in CHF patients met with increased mortality in the
anti-TNF group compared with placebo.16 However, one
should be prudent when interpreting the onset of CHF in
patients with RA receiving anti-TNF therapy, as cardio-
vascular diseases are a leading cause of death among
these patients.
Perhaps more interestingly, therapy of RA patients with
TNF blockers might also have beneficial consequences,
other than those related to the inflamed joints. 
An increased mortality due to cardiovascular and cerebro-
vascular diseases is seen in RA patients when compared
with the general population. The contribution of inflam-
mation to the development of atherosclerosis and insulin
resistance is now regarded to be more and more important,
and TNF has emerged as playing a key role in these
processes. In addition, markers of inflammation, such
as C-reactive protein (CRP), are now considered to be
important predictors of future acute cardiovascular
events. In that respect, we recently investigated whether
the profile of cardiovascular risk factors in such patients
ameliorates during anti-TNF treatment.17 This would not be
unexpected, since TNF is known to increase interleukin-6
(IL-6) and CRP and induce proatherogenic changes in
lipid profile. 
We found that anti-TNF treatment with adalimumab
enhanced the concentrations of HDL cholesterol and
decreased the concentrations of CRP and IL-6 within 
14 days. To what extent these changes remain during
prolonged observation and translate into a lower cardio-
vascular risk is the subject of future studies.
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